1. Pink Sheet
  2. >>Legal & IP

Insys ‘Reimbursement Unit’ Fraudulently Boosted Fentanyl Rxs, DOJ Charges

 
• By Brenda Sandburg

Six former Insys executives and managers arrested on changes of misleading insurers and pharmacy benefit managers into authorizing payments for Subsys sublingual fentanyl pain medicine.

BusinessmanBehindBars_1200-x-675

The Department of Justice alleges that former Insys Therapeutics Inc. executives and managers created a reimbursement unit to increase prior authorizations for the company’s fentanyl-based spray Subsys. The government says the individuals then disguised the unit in calls to insurers and pharmacy benefit managers to get them to believe they were getting calls directly from doctors’ offices.

The US Attorney’s Office for the District of Massachusetts announced that six former employees of Insys, including president and CEO...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

Sanofi Secures EU Fast-Track Status For ‘Game-Changing’ Sleeping Sickness Drug

 
• By Neena Brizmohun

If approved, Sanofi’s acoziborole could become the first single-dose oral treatment for sleeping sickness.

Mexico Speeds Up Market Access With Regulatory Reliance Guidelines

 
• By Francesca Bruce

Mexico’s drugs regulator will be able to grant quicker drug approvals based on decisions issued by World Health Organization listed authorities and founding ICH members.

UK Approves Biogen’s Qalsody After England Revises Reimbursement Approach

 
• By Eliza Slawther

Biogen has U-turned on its original decision not to file Qalsody for marketing approval in the UK for treating certain patients with amyotrophic lateral sclerosis. The move appears to have been triggered by a change in the reimbursement pathway agreed for the product.